SIETES :: 93013 citas

Resultados de la búsqueda por ANTECEDENTES REFINAR BÚSQUEDA

1.

Reymolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, et al.. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med 2020:1. [Ref.ID 103604]

2.

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of covid-19. N Engl J Med 2020:1 de mayo. [Ref.ID 103603]

3.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med 2020:1 de mayo. [Ref.ID 103602]

4.

Zhang PZhi L, Cai J, Lei F, Qin J-J, Xie J, Liu Y-M, Zhao Y-C, Huang X, Lin L, Xia M, Chen M-M, Cheng X, Zhang X, Guo D, Peng Y, Ji Y-X, Chen J, She Z-G, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, et al.. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Research 2020:17 de abril. [Ref.ID 103594]

5.

Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors With severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiology 2020:23 de abril. [Ref.ID 103593]

6.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

7.

Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy. A review. JAMA 2019;321:15 de enero. [Ref.ID 103008]

8.

Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7. [Ref.ID 100280]

9.

Anónimo. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). U.S. Food and Drug Administration 2015:30 de marzo. [Ref.ID 98888]

10.

Anónimo. New oral anticoagulants apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto): risk of serious haemorrhage - clarified contraindications apply to all three medicines. Drug Safety Update 2013;7:octubre. [Ref.ID 96225]

11.

Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-polylysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol 2013;1:258-63. [Ref.ID 95645]

12.

Tebé C, Miquel del Río L, Di Gregorio S, Casas L, Estrada M-D, Kotzeva A, Espallargues M. Validació del model predictiu de fractura major osteoporòtica FRAX en una cohort històrica de dones espanyoles. Annals Med (Barc) 2012;95:169-74. [Ref.ID 93265]

13.

Anónimo. Febuxostat (Adenuric) stop treatment signs or symptoms of serious hypersensitivity (eg. serious skin reactions or systemic hypersensitivity) occur. Drug Safety Update 2012;5:junio. [Ref.ID 92646]

14.

Anónimo. FDA issues cautions on use of fingolimod in MS patients with heart, stroke problems.. DIA Daily 2012:15 de mayo. [Ref.ID 92625]

15.

Gillison ML, Broutian T, Pickard RKL, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693-703. [Ref.ID 92368]

16.

Stein CM, Ray WA. The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med 2010;363:1367-70. [Ref.ID 89434]

17.

Rosen CJ, Khosla S. Placebo-controlled trials in osteoporosis - Proceeding with caution. N Engl J Med 2010;363:1365-7. [Ref.ID 89433]

18.

Pearce SHS, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010;340:142-7. [Ref.ID 87640]

19.

Sahota O. Reducing the risk of fractures with calcium and vitamin D. BMJ 2010;340:109-11. [Ref.ID 87576]

20.

The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:139. [Ref.ID 87575]